Compound having S1P receptor binding potency and use thereof

Details Compound having S1P receptor binding potency and use thereof Compound having S1P receptor binding potency and use thereof

2005-06-22

2011-10-18

Sullivan, Daniel (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S316000, C514S480000

Reexamination Certificate

active

08039674

ABSTRACT:
Provided are: a compound represented by formula (I):(wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocyclic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof, a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

REFERENCES:
patent: 4148897 (1979-04-01), Oka et al.
patent: 2007/0167425 (2007-07-01), Nakade et al.
patent: 0 400 495 (1990-12-01), None
patent: 1 270 545 (2003-01-01), None
patent: 1 283 039 (2003-02-01), None
patent: 1 334 732 (2003-08-01), None
patent: WO 98/38156 (1998-09-01), None
patent: 01/38325 (2001-05-01), None
patent: WO 02/092068 (2002-11-01), None
patent: 03/062248 (2003-07-01), None
patent: 03/062252 (2003-07-01), None
patent: WO 03/055521 (2003-07-01), None
patent: WO 2004/096752 (2004-11-01), None
patent: WO 2004/096757 (2004-11-01), None
patent: WO 2005/020882 (2005-03-01), None
patent: WO2005020882 (2005-03-01), None
Morissette, S. et al. Advanced Drug Delivery Reviews 56 (2004) 275-300.
Lens et al. British Journal of Nursing 17 (2008) 300-305 (abstract).
Vippagunta et al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Testa, B. Biochemical Pharmacology 68 (2004) 2097-2106.
Stella, V. Expert Opin Ther. Patents (2004) 14(3) 277-280.
Wolff M. Burger's Medicinal Chemistry and Drug Discovery 5thEdition 1995, 975-977.
Sumalainen et al. American Journal of Pathology 2005 166(3), 773-781.
Ettmeyer, P. Journal of Medicinal Chemistry 47(10) 2004, 2393-2404.
Divers et al. Cutis. 73(4) 2004, 257-262 (abstract).
Sausville et al. Cancer Research 66, 2004, 3351-3354.
Johnson et al. British Journal of Cancer 2001, 84(10) 1424-1431 (abstract).
P. Pevarello, et al.; “Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives”; Journal of Medicinal and Pharmaceutical Chemistry, American Chemical Society, Easton, US; vol. 41, 1998, pp. 579-590, XP0090740418.

Affiliated with

Also associated with

Rating

Compound having S1P receptor binding potency and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compound having S1P receptor binding potency and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound having S1P receptor binding potency and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283918